CASSY®
Compact Automated Scalable SYnthesis.
- [68Ga]Ga-tracers
- [177]Lu-tracers
- [64]Cu-tracers
- [89]Zr-tracers
- Maximum flexibility
CASSY® supports the purification and radiolabelling of a wide range of radioisotopes and radiotherapeutics.
- Streamlined production
CASSY®’s ready-to-use consumables and plug-and-play design automate all production steps, reducing manual operations and increasing efficiency.
- Valves
18
- Detectors
1 internal and 2 optional (external)
- Syringe drivers
Up to 20 ml
- Auxiliary signal ports
4 digital I/0, 2 analog input
- Heating & Reactor ovens
Up to 180°
- Hot cell compatibility
Up to 4 units in a standard hot cell
- Peristaltic pump
Up 15 ml/min
- Dimensions
190 x 190 x 245 mm / 7.5 x 7.5 x 9.6 in (w x d x h)
- User-friendly
Boost your productivity with CASSY®, IBA’s user-friendly synthesizer designed to make robust production effortless.
- Versatile
CASSY® provides maximum flexibility, allowing you to purify and label a wide range of radioisotopes: 68Ga,177Lu, 64Cu,89Zr and more to come.
- Compact
With its compact design, CASSY® fits seamlessly into your workflow, allowing up to 6 units in a single hot cell to maximize space and production.
- Your consumables by Fluidomica
CASSY® cassettes integrate all necessary components for processes: reagents, connections, and ancillaries. Fluidomica is an integrated IBA company, specializing in the development, production, and sales of disposable cassettes.
Interested to learn more about CASSY®?
Download product information
Find out everything you need to know about CASSY®.
You don’t only have to take our word for it. Here is what others say about CASSY®.
The introduction of CASSY® represents a pivotal advancement in our dedication to theranostic innovation.
“CASSY® is a game changer for radiopharmaceuticals manufacturing, delivering superior quality and more dependable results for patients.”
- 15/12/2025
New era for FluidomicaIn 2016, our dream started to become a reality: facilitate radiosynthesis by producing ready-to-use consumables with a plug-and-play approach.
In 2019, we started the production of disposable tubing kits and other consumables, in its ISO7 cleanroom at Biocant, Portugal.
After 9 years, we are proud of what we achieved!
From a start-up to an integrated IBA company, we specialize in the development, production, and sale of disposable cassettes for radioisotopes production and cyclotron liquid target solutions used in radiometals' production.
- 19/12/2025
IBA acquires ORA expanding its strategic leadership in Nuclear MedicineLouvain-la-Neuve, Belgium, December 19, 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium.
This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient therapy.
The combination of IBA cyclotron leadership with ORA’s cutting-edge technology provides one of the most competitive integrated solutions for hospitals and global radiopharmacy networks looking for high productivity and access to labelling of advanced radioisotopes.
This acquisition complements IBA’s existing nuclear medicine strategic initiatives including the co-founding of PanTera for the production of Ac-225, and the shaping of the Accelerate.EU program, as well as the ongoing collaboration with Framatome to explore opportunities in the production of At-211. It is an additional step for IBA on its journey to bring innovation in care to patients and to accelerate the translation of innovative nuclear medicine solutions from bench to bedside.
The transaction, for a total consideration of € 15-20 million on a cash-free, debt-free basis, is immediately accretive to IBA Technologies’ revenue and EBITDA and is expected to generate revenue synergies. Financed through IBA’s own funds and existing credit facilities, the acquisition will not have material impact on IBA’s 2025 financial guidance or mid-term outlook.
“Joining forces with IBA opens exciting opportunities to scale our NEPTIS® technology and accelerate innovation in radiochemistry.” said Vincent Tadino, Founder and Chief Executive Officer of ORA. “Together, we will continue to push the boundaries of PET and therapeutic radiochemistry, ensuring our customers have access to the most advanced and reliable solutions for radiopharmaceutical production.”
“ORA’s acquisition accelerates our mission to deliver integrated solutions from isotope production to patient-ready therapies, making advanced cancer treatments and diagnostics more accessible worldwide” stated Charles Kumps, President of IBA RadioPharma Solutions, “I am particularly excited that Vincent will continue to lead as Chief Technology Officer of ORA, bringing his vision and deep expertise to our joint efforts.”
